Uc Science Today

There was a lot of exciting University of California research news this past week. First the Food and Drug Administration approved a new drug that could halt Multiple Sclerosis. We had previously spoken to neurologist Bruce Cree of the University of California, San Francisco about his work testing the new drug, called ocrelizumab. At the time, Cree explained that it actually targets B-cells in the human body, blocking the inflammation that drives the disease. He explained that most MS therapies in the past targeted T-cells, which often had serious side effects. "You can have profound immunological effects and clinical benefits by just targeting B-cells alone. And I think this is actually an important advance for multiple sclerosis because when you just target B-cells without affecting T-cells, you have less of a potential for adverse events due to broad spectrum immune suppression." Really, such great news considering this devastating disease affects hundreds of thousands of Americans and more than 2.3 mill